Revolution Medicines Inc Ordinary Shares RVMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
-
Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
-
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
-
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
-
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
-
Revolution Medicines Gets FDA Breakthrough Designation for Cancer Treatment
-
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
-
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
Trading Information
- Previous Close Price
- $182.15
- Day Range
- $180.00–197.14
- 52-Week Range
- $52.48–224.31
- Bid/Ask
- $195.55 / $196.70
- Shares Outstanding
- 214.34M
- Market Cap
- $42.13B
- Volume/Avg
- 3M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 883
- Website
- https://www.revmed.com
Valuation
|
Metric
|
RVMD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 16.16 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RVMD
|
|---|---|
Quick Ratio | 11.12 |
Current Ratio | 11.38 |
Interest Coverage | −30.46 |
Quick Ratio
RVMD
Profitability
|
Metric
|
RVMD
|
|---|---|
Return on Assets (Normalized) | −46.51% |
Return on Equity (Normalized) | −68.83% |
Return on Invested Capital (Normalized) | −62.48% |
Return on Assets
RVMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<j&q!>c | LOCK|T>KY | $130B | |||
| Moderna Inc
MRNA
| LOCK|FjGh!! | LOCK|Nn> | $97B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^KW>^QV | LOCK|b<$Q | $83B | |||
| argenx SE ADR
ARGX
| LOCK|>#%@X? | LOCK|>&$ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>?c&$? | LOCK|#t | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|K<lr^< | LOCK|^M%#Q | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|mMr&w>zT | LOCK|>k$p | $28B | |||
| Incyte Corp
INCY
| LOCK|Z>jN$X | LOCK|>P | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|JZn&rh | LOCK|>H | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|t<pj&R | LOCK|&& | $14B |
United States